In this article by Contract Pharma, Thierry Van Nieuwenhove, the CEO of Quotient Sciences discusses how the CDMO is positioning itself to stay ahead of the curve and what are the most significant trends in the CDMO industry.
Mr. Van Nieuwenhove shares a hopeful view of the industry and signs of industry recovery after recent challenges linked to post COVID-19 slowdown and biotech financing challenges. He points to the growing interest in GLP-1 therapies, which are being used for more than just diabetes and weight loss, thanks to improvements in how these drugs are now being formulated as oral products.
"We know that most approved peptide-based medicines are administered via injection and that remains a drawback for some patients," he says. "Innovations in peptide chemistry and drug delivery are enabling more peptides to be optimised for oral administration, making it easier for patients to start and continue their treatment."
Van Nieuwenhove also highlights the importance of the Quotient Sciences Translational Pharmaceutics platform for integrated drug development. This platform brings together services in a streamlined process, managed under a single product manager and scope of work. “Expanding our Translational Pharmaceutics platform in the U.S. remains a key objective.” he added. Translational Pharmaceutics has been used for nearly two decades in the development of new therapies for global clients, from facilities in both the U.K. and U.S.
With a focus on strong partnerships and practical solutions, Quotient Sciences aims to help bring new treatments to patients more quickly and efficiently. Continue reading the full article on Contract Pharma.